Dienstag, 24. Oktober 2017
Benutzername
Passwort
Registrieren
Passwort vergessen?

Home
e-journal
Der Aktuelle Fall
CME online
News
Gesundheitspolitik
Fachgesellschaften
Therapiealgorithmen
Videos
Veranstaltungen
Broschüren


Suche
Archiv
Buchbestellung
Newsletter
Probe-Abo
Impressum


journalmed.de


Anzeige:
 
 
Anzeige:
 
 

JOURNAL ONKOLOGIE – NEWS
Zurück
Zurück
E-Mail
Email
Drucken
Drucken
Zum Bewerten bitte anmelden!
18. Mai 2015

ASCO-Jahrestagung 2015: Vorstellung neuer Daten zu Pembrolizumab in der Therapie von 10 unterschiedlichen Krebsarten

Bei der 51. Jahrestagung der American Society of Clinical Oncology (ASCO) vom 29.5-2.6.2015 in Chicago werden neue Ergebnisse zu Pembrolizumab vorgestellt. Der Wirkstoff zeigt Anti-Tumor-Aktivität bei 5 weiteren Tumorentitäten: Kolonkarzinom, Ösophaguskarzinom, Ovarialkarzinom, Nierenzellkarzinom und SCLC. Des Weiteren werden erste Ergebnisse über Daten zum defekten DNA-Mismatch-Repair-System beim Kolorekatalkarzinom und anderen Krebsarten sowie Nanostring-RNA-Daten zum Melanom, Kopf-Halstumore und Magenkrebs präsentiert.

Anzeige:
 
 

Eine Liste von ausgewählten Veranstaltungen wie Vorträge, "clinical science" Symposien und Posterdiskussionen, die im ASCO Programm enthalten sind, finden sie unten stehend.

Kopf-Halstumoren

  • (Abstract #LBA6008) Late-Breaker Presentation: Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. T. Seiwert. Monday, June 1, 3:39 PM - 3:51 PM CDT. Location: S100bc. ASCO Press Program, Friday, May 29, 1:00 PM CDT.
  • (Abstract #6017) Poster Discussion: Inflamed-phenotype gene expression signatures to predict benefit from the anti-PD-1 antibody pembrolizumab in PD-L1+ head and neck cancer patients. T. Seiwert. Saturday, May 30, 1:15 PM - 4:45 PM CDT (poster session). Location: S Hall A. 4:45 PM - 6:00 PM CDT (discussion). Location: S406.

Melanom

  • (Abstract #9005) Oral Presentation: Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. A. Daud. Saturday, May 30, 2:39 PM - 2:51 PM CDT. Location: E354b.
  • (Abstract #3000) Oral Presentation: Atypical patterns of response in patients (pts) with metastatic melanoma treated with pembrolizumab (MK-3475) in KEYNOTE-001. J. Wolchok. Monday, June 1, 1:15 PM - 1:27 PM CDT. Location: S406.
  • (Abstract #3001) Oral Presentation: Association of response to programmed death
    receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferoninflammatory immune gene signature. A. Ribas. Monday, June 1, 1:27 PM - 1:39 PM CDT. Location: S406.
    (Abstract #3009) Poster Discussion: Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): Data from the KEYNOTE-029 phase 1 study. M. Atkins. Saturday, May
    30, 8:00 AM - 11:30 AM CDT (poster session). Location: S Hall A. 3:00 PM - 4:15 PM CDT
    (discussion). Location: S406.

Lungenkrebs

  • (Abstract #8011) Clinical Science Symposium: Phase I study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D. A. Patnaik. Sunday, May 31, 4:54 PM - 5:06 PM CDT. Location: E Hall D1.
  • (Abstract #7502) Oral Presentation: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE-028. P. Ott. Saturday, May 30, 3:48 PM - 4:00 PM CDT. Location: E Hall D1.

Weitere Krebsarten

  • (Abstract #LBA100) Late-Breaker Presentation: PD-1 blockade in tumors with mismatch repair deficiency. D. Le. Saturday, May 30, 8:05 AM – 8:17 AM CDT. Location: E Hall D1. ASCO Press Program, Friday, May 29, 1:00 PM CDT.
  • (Abstract #4001) Oral Presentation: Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. Y. Bang. Sunday, May 31, 8:12 AM - 8:24 AM CDT. Location: E Hall D2.
  • (Abstract #4010) Clinical Science Symposium: Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. T. Doi. Sunday, May 31, 4:54 PM - 5:06 PM CDT. Location: E Hall D2.
  • (Abstract #4502) Oral Presentation: Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012. E. Plimack. Monday, June 1, 10:09 AM - 10:21 AM CDT. Location: E Arie Crown Theater.
  • (Abstract #5510) Clinical Science Symposium: Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. A. Varga. Monday, June 1, 3:12 PM - 3:24 PM CDT. Location: E354b.

 

Quelle: MSD
 
Zurück
Zurück
E-Mail
Email
Drucken
Drucken
Zum Bewerten bitte anmelden!



Anzeige:
 
 
Anzeige:
 
 
 
 
Themen
CML
CUP
NET
Nutzen Sie auch die Inhalte von journalmed.de, um sich zu Informieren.
Mediadaten
Hilfe
Copyright © 2014 rs media GmbH. All rights reserved.
Kontakt
Datenschutz
AGB
Fakten über Krebs